Journal of Clinical Oncology
Articles in this Issue
Clinical outcomes with definitive surgery or radiotherapy after neoadjuvant immunochemotherapy in stage II-III NSCLC: Full cohort pragmatic analysis.
8059 Background: Recently, several landmark randomized controlled trials on neoadjuvant immunochemotherapy (NIC) have significantly changed the treatment...
A phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX43 (anti-PD-L1 ADC) in patients with advanced/metastatic solid tumors.
3025 Background: Antigens highly expressed in tumors such as HER2 and TROP2 have been widely investigated as antibody-drug conjugate (ADC) targets, leadin...
Survival of patients diagnosed with stage IV cancer in 2020 based on COVID-19 status.
e24041 Background: The COVID-19 pandemic disrupted the evaluation and treatment of many cancer patients. Contracting a COVID-19 infection could further ex...
FORTE: A phase 2 master protocol assessing plixorafenib for BRAF-altered cancers.
TPS2091 Background: Plixorafenib (FORE8394; PLX8394) is a novel, oral, small-molecule BRAF inhibitor highly selective for BRAF V600 monomers and BRAF-cont...
Prospective decision impact study of the Breast Cancer Index: Results from the BCI Registry study.
531 Background: The Breast Cancer Index (BCI) is a validated gene expression assay that provides an individualized risk of late distant recurrence and pre...
Substudy G of the Canadian cancer trials group (CCTG) IND.234: PC_BETS (V)—A circulating tumor DNA (ctDNA)–directed phase II study of carboplatin in patients (Pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC).
5058 Background: PC-BETS registered pts with mCRPC for ctDNA-based genomic screening. A molecular tumor board (MTB) assigned pts to sub-studies (SS) based...
Brain metastasis in patients with primary gastrointestinal malignancy on anti-HER2 therapy.
e16067 Background: The incidence of brain metastasis in gastrointestinal (GI) malignancies is rare, estimated at less than 1%. However, its occurrence is...
Research productivity of international medical graduate (IMG) hematology and oncology fellows in the United States (US).
9003 Background: IMGs constitute one-third of practicing oncologists in the US. However, there is limited data on their academic contributions. We analyze...
Phase II study of short-course radiotherapy (SCRT) followed by consolidation chemotherapy with FOLFOXIRI as total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC) patients (pts): The ShorTrip study.
3592 Background: TNT is a recognised option for the treatment of LARC. The efficacy of both FOLFIRINOX followed by long-course CTRT and SCRT followed by F...
Clinical outcome of comprehensive genomic profiling (CGP) driven personalized treatment in cancer patients based on the decision of Apex Molecular Tumor Board (MTB): An Indian multi-centric real-world data.
e23013 Background: CGP followed by MDT-based therapy recommendation plays a synergistic role in improving clinical outcomes of cancer patients. CGP in cli...
The economics of cancer immunotherapy: A five-year Medicare B expenditure analysis of checkpoint inhibitors.
2569 Background: Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, prompting a comprehensive analysis of Medicare Part B spending tre...
The effect of HIFU treatment on liver metastasis of colorectal cancer in mice and its impact on immunity.
3088 Background: The liver represents the predominant site for metastasis in colorectal cancer, with over 85% of cases exhibiting the microsatellite stabl...
Mutational signature differences in paired tissues of triple-negative breast cancer receiving neoadjuvant therapy: Preliminary analysis.
e12555 Background: Triple-negative breast cancer (TNBC), accounting for 15%–20% of breast cancers, is aggressive, with higher relapse rates and worse outc...
Outpatient treatment-related toxicity after hospital discharge among patients receiving lifileucel for advanced melanoma.
9557 Background: While inpatient toxicity associated with tumor infiltrating lymphocyte (TIL) therapy and IL-2 administration is well characterized, risks...
Recurrence rates after anti-PD1 discontinuation for advanced melanoma: A systematic review and single-arm meta-analysis.
e21536 Background: The introduction of immune checkpoint inhibitors, particularly anti-PD1 agents, has transformed the treatment landscape for unresectabl...
Darolutamide plus goserelin for androgen receptor-positive salivary gland cancers: Results of phase 2 study (DISCOVARY).
6007 Background: No standard treatment exists for unresectable locally advanced (LA) or recurrent/metastatic (R/M) salivar...
Association of mitotic circulating tumor cells with clinical outcomes in metastatic breast cancer.
e15045 Background: Increased cancer cell mitosis in tumor tissue is widely regarded as an indicator of aggressive disease, a predictor of shorter survival...
Emiltatug ledadotin (Emi-Le): A B7-H4-directed dolasynthen antibody-drug conjugate (ADC) being investigated in phase 1 dose expansion in patients with triple negative breast cancer who received at least one prior topoisomarase-1 inhibitor ADC.
TPS1141 Background: Breast cancer is the leading cause of cancer death for women worldwide, with triple-negative breast cancer (TNBC) considered one of th...
Development and validation of a novel circulating tumor cell response stratification criteria for metastatic castration-resistant prostate cancer clinical trials.
e17072 Background: While circulating tumor cells (CTC) have been used in metastatic castration-resistant prostate (mCRPC) clinical trials, established res...
Prognostic factors and survival outcomes in adrenocortical carcinoma: A comprehensive analysis of the SEER and TCGA databases.
e16620 Background: Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy characterized by high recurrence rates and poor response to treatmen...
The role of occupational carcinogens in laryngeal cancer: A global trend analysis (1990-2021).
e18118 Background: Laryngeal cancer is a significant global health burden, with occupational carcinogens such as Asbestos and Wood Dust recognized as risk...
Efficacy of definitive radiotherapy with concurrent and adjuvant immune checkpoint inhibitors in patients with locally advanced head and neck squamous cell carcinoma (LA HNSCC).
6062 Background: Head and neck squamous cell carcinoma (HNSCC) is the most common type of head and neck cancers, associated with a high incidence and mort...
A phase II study of binimetinib plus imatinib in patients with unresectable KIT-mutant melanoma.
TPS9605 Background: Patients (pts) with melanoma refractory to immune checkpoint inhibition (ICI) remain in need of rational therapeutic options. Pts with...
imNEO: High-accuracy neoantigen prediction through AI-based integrated analysis of multiple immunogenicity-related factors.
e14639 Background: Neoantigens have emerged as compelling targets for cancer vaccines, with early clinical trials confirming their safety and efficacy. Ac...
Molecular profile and disparity of care in metastatic non small cell lung cancer in a low middle income country: A retrospective analysis.
e20517 Background: Driver mutation analysis has transformed the treatment landscape of Non Small Cell Lung Cancer (NSCLC), but there exists a significant...